The CpG island methylator phenotype increases the risk of high-grade squamous intraepithelial lesions and cervical cancer

Loaeza-Loaeza, Jaqueline; Illades‐Aguiar, Berenice; Moral-Hernández, Oscar Del; Castro‐Coronel, Yaneth; Leyva‐Vázquez, Marco Antonio; Dircio-Maldonado, Roberto; Ortíz-Ortíz, Julio; Hernández-Sotelo, Daniel

doi:10.1186/s13148-021-01224-0

Cited by 7 publications

(3 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MyoD1 (Met-set); F: 5’-GACGGTTTTCGACGGTTT-3’, R: 5’-GCCCGAAACCGAATACAC-3’ (Product Size (bp) = 184), MyoD1 (Unmeth-set); F: 5’-ATTTGATGGTTTTTGATGGTTT-3’, R: 5’-CACACACATACTCATCCTCACA-3’ (Product Size (bp) = 213) 19 , 20 .…”

Section: Mterials and Methodsmentioning

confidence: 99%

The Association of Methylation Status and Expression Level of MyoD1 with DNMT1 Expression Level in Breast Cancer Patients

Khojastehpour,

Foroughi,

Gheibi

et al. 2023

IJHOSCR

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the most common malignancy in women worldwide. The methylation status of MyoD1, a tumor suppressor gene, is enrolled in various cancers, i.e., BC. Various studies showed the impact of MyoD1 epigenetic dysregulation in BC. This study aimed to investigate the methylation status and expression level of MyoD1 in BC patients and its association with the expression of DNMT1. Materials and Methods: This case-control study was conducted on 30 cases (pathology-confirmed ductal carcinoma) and 18 controls (fibroadenoma and fibrocystic masses), referred to Velayat Hospital, Qazvin, Iran. The expression of the MyoD1 and DNMT1 and the promoter methylation of the MyoD1 were evaluated in tissue blocks of BC patient masses using qRT-PCR and MS-PCR assays, respectively. SPSS 24.0 was used to analyze the data. Results: The MyoD1 promoter is hypermethylated in BC patients compared to controls (p =0.001). The expression level of MyoD1 in BC patients was significantly reduced compared to controls (fold change =0.13, p =0.042). In addition, in BC patients, the reduced expression level of MyoD1 was significantly associated with methylation of the MyoD1 promoter (p =0.001). There is no significant difference between the expression level of DNMT1 in BC patients and controls (p =0.197). A significant association is found between the expression of DNMT1 and the methylation status of the MyoD1 promoter (p =0.038). Discussion: The expression level of MyoD1 is affected by the methylation status of the promoter of this gene. Moreover, the expression level and methylation status of MyoD1 are correlated with clinical parameters.

show abstract

Section: Mterials and Methodsmentioning

confidence: 99%

The Association of Methylation Status and Expression Level of MyoD1 with DNMT1 Expression Level in Breast Cancer Patients

Khojastehpour,

Foroughi,

Gheibi

et al. 2023

IJHOSCR

View full text Add to dashboard Cite

show abstract

“…Similarly, supplementation of vitamin C in the extracellular medium of embryonic stem cells (ESC) induces a global increase in cytosine hydroxymethylation, at the expense of the 5 mC ( 33 ), leading to a rapid reprogramming of fibroblasts into induced pluripotent stem cells (iPSCs). In cancer, a global hypomethylation epigenetic profile, together with inter-dispersed hypermethylated CpG islands (CIMP), constitutes a prognostic biomarker in multiple tumours ( 34 ). A specific point mutation in the isocitrate dehydrogenase ( IDH1 ) gene in gliomas results in a mutant enzyme that generates high levels of the oncometabolite 2-hydroxyketoglurate, inhibiting α-KG-dependent TET enzymes ( 35 ).…”

Section: Metabolic Regulations Of Epigenetic Marksmentioning

confidence: 99%

Metabolo-epigenetic interplay provides targeted nutritional interventions in chronic diseases and ageing

Gómez de Cedrón,

Moreno Palomares,

Ramírez de Molina

2023

Front. Oncol.

View full text Add to dashboard Cite

Epigenetic modifications are chemical modifications that affect gene expression without altering DNA sequences. In particular, epigenetic chemical modifications can occur on histone proteins -mainly acetylation, methylation-, and on DNA and RNA molecules -mainly methylation-. Additional mechanisms, such as RNA-mediated regulation of gene expression and determinants of the genomic architecture can also affect gene expression. Importantly, depending on the cellular context and environment, epigenetic processes can drive developmental programs as well as functional plasticity. However, misbalanced epigenetic regulation can result in disease, particularly in the context of metabolic diseases, cancer, and ageing. Non-communicable chronic diseases (NCCD) and ageing share common features including altered metabolism, systemic meta-inflammation, dysfunctional immune system responses, and oxidative stress, among others. In this scenario, unbalanced diets, such as high sugar and high saturated fatty acids consumption, together with sedentary habits, are risk factors implicated in the development of NCCD and premature ageing. The nutritional and metabolic status of individuals interact with epigenetics at different levels. Thus, it is crucial to understand how we can modulate epigenetic marks through both lifestyle habits and targeted clinical interventions -including fasting mimicking diets, nutraceuticals, and bioactive compounds- which will contribute to restore the metabolic homeostasis in NCCD. Here, we first describe key metabolites from cellular metabolic pathways used as substrates to “write” the epigenetic marks; and cofactors that modulate the activity of the epigenetic enzymes; then, we briefly show how metabolic and epigenetic imbalances may result in disease; and, finally, we show several examples of nutritional interventions - diet based interventions, bioactive compounds, and nutraceuticals- and exercise to counteract epigenetic alterations.

show abstract

“…1 Most of the cases are seen in developing countries. 2 The low incidence and mortality of cervical cancer in developed countries depend on screening programs and human papillomavirus (HPV) vaccination programs. Almost all cases of cervical cancer are caused by HPV infections.…”

Section: Introductionmentioning

confidence: 99%

Should Women Between the Ages of 25 and 30 Get Tested for HPV?

Gündüz¹,

Ağaçayak²,

Bozbay³

et al. 2022

Eur J Ther

View full text Add to dashboard Cite

Objectives:The aim of this study is to discuss whether performing the human papillomavirus test on women aged 25-30 in Turkey has any effect on preventing cervical cancer. It is aimed to reevaluate the screening program. Methods: A total of 400 patients between the ages of 25-30 who had the Papanicolaou smear and the human papillomavirus test were included in our study. Pap smear and the human papillomavirus test were performed again on the patients with a positive human papillomavirus test for high-risk types in accordance with the screening program. Demographical and clinical characteristics of the patients were recorded. The incidence of human papillomavirus test positivity with a high risk among patients aged 25-30, regression, and persistence ratios were calculated. Results: The incidence of human papillomavirus test positivity with a high risk among patients aged 25 to 30 was found to be 7%. Human papillomavirus persistence ratio was 17.6% and the regression ratio was 82.4%. Among patients with a positive high-risk human papillomavirus test between the ages of 25 and 30, human papillomavirus 16 was found in 47.1% of the patients. For one of our patients with a persistent human papillomavirus 16 positivity, conization was performed after the cervical biopsy. Conclusion:We believe that human papillomavirus, which plays an important role in the etiology of cervical cancer, should be screened from the age of 25. This way, we can catch and treat precursor lesions of cervical cancer at earlier ages and lower the incidence and mortality of cervical cancer.

show abstract

The CpG island methylator phenotype increases the risk of high-grade squamous intraepithelial lesions and cervical cancer

Cited by 7 publications

References 67 publications

The Association of Methylation Status and Expression Level of MyoD1 with DNMT1 Expression Level in Breast Cancer Patients

The Association of Methylation Status and Expression Level of MyoD1 with DNMT1 Expression Level in Breast Cancer Patients

Metabolo-epigenetic interplay provides targeted nutritional interventions in chronic diseases and ageing

Should Women Between the Ages of 25 and 30 Get Tested for HPV?

Contact Info

Product

Resources

About